Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/11602
Title: | A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation | Authors: | Vos, R. Vanaudenaerde, B. M. Verleden, S. E. De Vleeschauwer, S. I. WIDYASTUTI, Anna Van Raemdonck, D. E. Schoonis, A. NAWROT, Tim Dupont, L. J. Verleden, G. M. |
Issue Date: | 2011 | Publisher: | EUROPEAN RESPIRATORY SOC JOURNALS LTD | Source: | EUROPEAN RESPIRATORY JOURNAL, 37 (1). p. 164-172 | Abstract: | Azithromycin reduces airway inflammation and improves forced expiratory volume in 1 s (FEV1) in chronic rejection or bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx). Azithromycin prophylaxis might prevent BOS. A double-blind randomised controlled trial of azithromycin (n=40) or placebo (n=43), initiated at discharge and administered three times a week for 2 yrs, was performed in 2005-2009 at the Leuven University Hospital (Leuven, Belgium). Primary end-points were BOS-free and overall survival 2 yrs after LTx; secondary end-points were acute rejection, lymphocytic bronchiolitis and pneumonitis rate, prevalence of pseudomonal airway colonisation or gastro-oesophageal reflux, and change in FEV1, airway and systemic inflammation over time. Patients developing BOS were assessed for change in FEV1 with open-label azithromycin. BOS occurred less in patients receiving azithromycin: 12.5 versus 44.2% (p=0.0017). BOS-free survival was better with azithromycin (hazard ratio 0.27, 95% CI 0.092-0.816; p=0.020). Overall survival, acute rejection, lymphocytic bronchiolitis, pneumonitis, colonisation and reflux were comparable between groups. Patients receiving azithromycin demonstrated better FEV1 (p=0.028), and lower airway neutrophilia (p=0.015) and systemic C-reactive protein levels (p=0.050) over time. Open-label azithromycin for BOS improved FEV1 in 52.2% patients. No serious adverse events were noted. Azithromycin prophylaxis attenuates local and systemic inflammation, improves FEV1 and reduces BOS 2 yrs after LTx. | Notes: | [Verleden, G. M.] Univ Hosp Gasthuisberg, Lung Transplantat Unit, B-3000 Louvain, Belgium. [Vos, R.; Vanaudenaerde, B. M.; Verleden, S. E.; De Vleeschauwer, S. I.; Willems-Widyastuti, A.] Katholieke Univ Leuven, Lab Pneumol, Leuven, Belgium. [Vos, R.; Vanaudenaerde, B. M.; Verleden, S. E.; De Vleeschauwer, S. I.; Willems-Widyastuti, A.; Van Raemdonck, D. E.; Schoonis, A.; Dupont, L. J.; Verleden, G. M.] Katholieke Univ Leuven, Lung Transplantat Unit, Leuven, Belgium. [Van Raemdonck, D. E.] Katholieke Univ Leuven, Lab Expt Thorac Surg, Leuven, Belgium. [Nawrot, T. S.] Katholieke Univ Leuven, Sch Publ Hlth, Unit Lung Toxicol Occupat & Environm Med, Leuven, Belgium. [Nawrot, T. S.] Univ Hasselt, Ctr Environm Sci, Diepenbeek, Belgium. geert.verleden@uz.kuleuven.be | Keywords: | Azithromycin;Bronchiolitis Obliterans Syndrome;Lung Allograft Rejection;Lung Transplantation;Obliterative Bronchiolitis | Document URI: | http://hdl.handle.net/1942/11602 | ISSN: | 0903-1936 | e-ISSN: | 1399-3003 | DOI: | 10.1183/09031936.00068310 | ISI #: | 000285752400025 | Rights: | ERS 2011 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2012 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
R_Vos.pdf Restricted Access | Published version | 432.79 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
165
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
192
checked on Apr 14, 2024
Page view(s)
66
checked on Sep 4, 2022
Download(s)
36
checked on Sep 4, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.